Pharmaceuticals

FDA Approves Phase 3 Study Protocol for Laekna’s LAE002 in Combination with LAE001 for the Treatment of Prostate Cancer

bexib
By bexib 0 Min Read

LAE002 Plus Phase III protocol approval for LAE001 comes as a result of positive Phase II data showing promising benefits in patients with metastatic castration-resistant prostate cancer (mCRPC).

You Might Also Like

FRONTIER 2 trial results show promise for Mim8 as potential treatment for hemophilia A

Cystic fibrosis drug improves outcomes in severe COVID-19 pneumonia

FDA Grants Premarket Approval to Endotronics’ Cordella Pulmonary Artery Sensor System to Support Heart Failure Patients

Phase 3 trial data showed that lenacapavir was 100% effective in preventing HIV in cisgender women.

Pharma Pulse 6/7/24: How much does a one-day delay really cost? BranchLab launches privacy-preserving healthcare advertising solution & more

Share This Article
Previous Article Make Learning Fun With 23 Awesome Business Ideas for Kids (2024)
Next Article Second US dairy farmer infected with HPAI – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Indian cash -free payments secure the $ 53 million US funded by PUBG Publisher Krafton.
Fintech
Late onboarding promotes clients’ losses at Singapore banks.
Fintech
The gorgeous spa Hotelgal Goma Resort will join the elegant hotel collection as the first member of the North Ireland
Hospitality & Tourism
Peter Navalo says, necessary for Trump’s economic success vision
Manufacturing